Results 1 to 10 of about 19,567,220 (299)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy [PDF]

Journal of Clinical Medicine, 2023
The landscape of melanoma treatment has undergone a dramatic revolution in the past decade. The use of oncolytic viruses (OVs) represents a novel therapeutic approach that can selectively infect and lyse tumor cells and induce local and systemic ...
Jian Ye, Holly Yin
exaly   +7 more sources

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma [PDF]

Cancers, 2021
Simple Summary Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first oncolytic viral immunotherapy to be approved for the local treatment of unresectable metastatic stage IIIB/C–IVM1a melanoma.
Pier Francesco Ferrucci, Laura Pala, Fabio Conforti   +2 more
exaly   +8 more sources

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells [PDF]

Frontiers in Immunology, 2021
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated ...
Julia Katharina Schwarze, Franceschini L, Jolien De Munck   +2 more
exaly   +10 more sources

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany [PDF]

Journal for ImmunoTherapy of Cancer, 2021
Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe.
Erika Richtig, Joanna Mangana, Christian Posch, Christoph Hoeller, Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Julian Kofler, Christine Hafner   +13 more
doaj   +11 more sources

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). [PDF]

J Surg Oncol, 2021
Talimogene laherparepvec (T‐VEC) is a genetically modified herpes simplex virus‐1‐based oncolytic immunotherapy and has been approved for the local treatment of unresectable (stage IIIB/C and IVM1a) cutaneous melanoma.
Mulder EEAP, Stahlie EHA, Verver D, Lemstra C, Been LB, Mooyaart AL, Brabander T, Vegt E, Verburg FA, van der Veldt AAM, Verhoef C, van Akkooi ACJ, Grünhagen DJ.   +12 more
europepmc   +10 more sources

Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy [PDF]

Journal for ImmunoTherapy of Cancer
In-transit metastases of malignant melanoma pose a significant clinical challenge, particularly in patients with contraindications to systemic therapies. While surgical excision and systemic immunotherapies remain standard treatments, localized therapies
Jeffrey Sosman, Sunandana Chandra, Danielle Lam, Jennifer Choi, Marisa Lenga, Esther Choi, Kirsten Johnson, Lauren Schiemann   +7 more
doaj   +5 more sources

Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. [PDF]

Curr Oncol Rep
As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Kalsi S, Galenkamp AL, Singh R, Khosla AA, McGranaghan P, Cintolo-Gonzalez J.   +5 more
europepmc   +6 more sources

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2023
Talimogene Laherparepvec (T‐VEC) is a first‐in‐class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery.
Malidi Ahamadi, Johannes Kast, Po‐Wei Chen, Xiaojun Huang, Sandeep Dutta, Vijay V. Upreti   +5 more
doaj   +3 more sources

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial [PDF]

BMC Cancer, 2022
Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates.
Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B. A. G. Haanen   +7 more
doaj   +4 more sources

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer [PDF]

npj Breast Cancer
Talimogene laherparepvec (T-VEC) is an oncolytic virus that is hypothesized to enhance responses to systemic therapy. This Phase 1b trial evaluated the safety and efficacy of intratumoral T-VEC plus chemotherapy (CT) or endocrine therapy (ET) for ...
Laura A. Huppert, Amelia S. Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Alexander Cheung, Mark Moasser, Melanie Majure, Michelle Melisko, Pamela Munster, Hope S. Rugo, Michael Campbell, Lawrence Fong, A. Jo Chien   +13 more
doaj   +3 more sources